Related Experiment Video
Updated: Mar 7, 2026

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
Published on: December 1, 2023
Impact of Short-Term Insulin Pump Therapy on Cardiometabolic Index in Patients With Newly Diagnosed Type 2 Diabetes
Xia Chen1, Shuya Li1, Zeren Chen1
1Department of Endocrinology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Objective:
This study aims to investigate the changes in cardiometabolic index (CMI) levels in newly diagnosed type 2 diabetes mellitus (T2DM) patients before and after undergoing short-term continuous subcutaneous insulin infusion (CSII) intensive treatment and analyse its correlation with insulin resistance.
Methods:
This study retrospectively collected data from 604 patients who were initially diagnosed with T2DM and received short-term CSII treatment during their hospitalisation in the Endocrinology Department of the Affiliated Hospital of Jiangsu University. Clinical data, blood glucose, insulin, C-peptide, blood biochemistry, and other indicators were collected before and after treatment, and CMI was calculated.
Results:
Short-term CSII treatment significantly improved blood glucose levels, insulin resistance, and pancreatic β-cell function in T2DM patients, while downregulating the CMI index (p = 0.002). Correlation analysis showed a positive correlation between CMI and HOMA-IR (p < 0.001) and a negative correlation between CMI and HOMA-β (p = 0.008). Stepwise linear regression model analysis revealed that CMI was independently associated with fasting C-peptide (FCP) before treatment (β = 0.291, p < 0.001); after treatment, CMI was associated with FCP (β = 0.160, p < 0.001) and HOMA-IR (β = 0.159, p < 0.001).
Conclusion:
After short-term intensive CSII treatment, the CMI level in newly diagnosed T2DM patients significantly decreased, indicating that intensive CSII treatment may have certain significance in improving cardiometabolic function.
More Related Videos
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Oral Hypoglycemic Agents: Biguanides and Glitazones

